Vanguard Group’s bluebird bio BLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-518,238
Closed -$2.53M 4282
2025
Q1
$2.53M Sell
518,238
-7,176
-1% -$43.2K ﹤0.01% 3416
2024
Q4
$4.38M Buy
525,414
+1,714
+0.3% +$15K ﹤0.01% 3323
2024
Q3
$5.45M Buy
523,700
+8,635
+2% +$144K ﹤0.01% 3242
2024
Q2
$10.1M Sell
515,065
-9,858
-2% -$197K ﹤0.01% 2909
2024
Q1
$13.4M Buy
524,923
+86,154
+20% +$2.21M ﹤0.01% 2798
2023
Q4
$12.1M Buy
438,769
+157,896
+56% +$9.63M ﹤0.01% 2841
2023
Q3
$17.1M Buy
280,873
+2,311
+0.8% +$162K ﹤0.01% 2605
2023
Q2
$18.3M Buy
278,562
+7,448
+3% +$545K ﹤0.01% 2628
2023
Q1
$17.2M Buy
271,114
+57,798
+27% +$6.6M ﹤0.01% 2652
2022
Q4
$29.5M Buy
213,316
+27,836
+15% +$3.92M ﹤0.01% 2442
2022
Q3
$23.5M Buy
185,480
+10,135
+6% +$1.15M ﹤0.01% 2559
2022
Q2
$14.5M Sell
175,345
-121,033
-41% -$9.39M ﹤0.01% 2795
2022
Q1
$28.7M Sell
296,378
-65,302
-18% -$8.62M ﹤0.01% 2583
2021
Q4
$72.3M Sell
361,680
-185,607
-34% -$43.8M ﹤0.01% 2147
2021
Q3
$135M Buy
547,287
+9,892
+2% +$2.83M ﹤0.01% 1812
2021
Q2
$223M Buy
537,395
+12,627
+2% +$5M 0.01% 1565
2021
Q1
$205M Buy
524,768
+25,806
+5% +$12.7M 0.01% 1564
2020
Q4
$280M Buy
498,962
+10,963
+2% +$6.95M 0.01% 1251
2020
Q3
$341M Buy
487,999
+17,306
+4% +$13.5M 0.01% 951
2020
Q2
$372M Buy
470,693
+171,463
+57% +$129M 0.01% 896
2020
Q1
$178M Buy
299,230
+8,081
+3% +$7.88M 0.01% 1199
2019
Q4
$331M Sell
291,149
-829
-0.3% -$901K 0.01% 1072
2019
Q3
$347M Sell
291,978
-1,993
-0.7% -$3.04M 0.01% 987
2019
Q2
$484M Sell
293,971
-83,747
-22% -$145M 0.02% 814
2019
Q1
$770M Buy
377,718
+7,424
+2% +$13.1M 0.03% 589
2018
Q4
$476M Buy
370,294
+13,675
+4% +$21M 0.02% 730
2018
Q3
$674M Buy
356,619
+32,646
+10% +$67.4M 0.03% 661
2018
Q2
$659M Buy
323,973
+1,680
+0.5% +$3.83M 0.03% 643
2018
Q1
$713M Buy
322,293
+9,395
+3% +$23.9M 0.03% 608
2017
Q4
$722M Buy
312,898
+28,502
+10% +$57.9M 0.03% 603
2017
Q3
$506M Buy
284,396
+9,633
+4% +$13.5M 0.02% 718
2017
Q2
$374M Buy
274,763
+26,546
+11% +$32M 0.02% 840
2017
Q1
$292M Buy
248,217
+10,908
+5% +$11.1M 0.02% 978
2016
Q4
$190M Buy
237,309
+26,110
+12% +$20.7M 0.01% 1206
2016
Q3
$185M Buy
211,199
+4,236
+2% +$3.07M 0.01% 1160
2016
Q2
$116M Buy
206,963
+25,738
+14% +$14.6M 0.01% 1418
2016
Q1
$99.8M Sell
181,225
-1,861
-1% -$1.14M 0.01% 1486
2015
Q4
$152M Buy
183,086
+13,487
+8% +$13.5M 0.01% 1170
2015
Q3
$188M Buy
169,599
+9,381
+6% +$17.1M 0.01% 1024
2015
Q2
$349M Buy
160,218
+53,147
+50% +$108M 0.02% 742
2015
Q1
$167M Buy
107,071
+47,741
+80% +$63M 0.01% 1137
2014
Q4
$70.5M Buy
59,330
+10,874
+22% +$7.27M 0.01% 1651
2014
Q3
$22.5M Buy
48,456
+17,429
+56% +$8.04M ﹤0.01% 2156
2014
Q2
$15.5M Buy
31,027
+13,828
+80% +$4.43M ﹤0.01% 2308
2014
Q1
$5.07M Buy
17,199
+7,640
+80% +$2.31M ﹤0.01% 2820
2013
Q4
$2.6M Buy
9,559
+1,459
+18% +$408K ﹤0.01% 3092
2013
Q3
$2.83M Buy
+8,100
New +$3.01M ﹤0.01% 3003

Other funds holding BLUE

Vanguard Group's BLUE Position: Q2 2025 in Review

Vanguard Group sold out of bluebird bio (BLUE) in Q2 2025, closing a stake of 518,238 shares — an estimated $2.53M sold.

Vanguard Group first reported a position in BLUE in Q3 2013 and held it in 47 quarters. The position peaked at $770M in Q1 2019. 3 funds tracked by Wall St. Rank hold BLUE as of Q2 2025.

  • Vanguard Group reported no remaining bluebird bio position as of Q2 2025 after selling out during the quarter.
  • Vanguard Group sold 518,238 bluebird bio shares in Q2 2025, an estimated $2.53M.
  • Vanguard Group first reported a position in bluebird bio in Q3 2013 and held it in 47 quarters.
  • Vanguard Group's bluebird bio position peaked at $770M in Q1 2019.
  • 3 funds tracked by Wall St. Rank held bluebird bio as of Q2 2025.

Based on Vanguard Group's 13F filing for Q2 2025, filed 11 Aug 2025.